You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion keeps Hemophilia therapy debate flowing in Latin America

A recent CLAHT Congress symposium restates current and future role of replacement therapy

read more 

CORPORATE

FSI SGR enters Kedrion share capital

The company continues with its growth and development strategy

read more 
  1. CORPORATE - 19-04-2017

    Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)

    The agreement aims to improve patient access to coagulation disorders treatments in Europe

    read more 
  2. EVENTS - 14-04-2017

    Kedrion Biopharma initiatives for World Hemophilia Day 2017

    The goal is to provide wider access to plasma-derived therapies for coagulation disorders the world over

    read more 
  3. CORPORATE - 24-03-2017

    New company AO Kirov Plasma established in Russia

    It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard

    read more 
  4. PLASMA & BIOTHERAPIES - 22-03-2017

    Article by Prof. Farrugia and Daniela Scaramuccia published on “Biologicals”

    International medical journal hosts review of contract plasma fractionation dynamics

    read more 

Pages

For more information please contact: pressoffice@kedrion.com